<?xml version="1.0" encoding="UTF-8"?>
<p id="Par16">Patients received a median of 7 cycles of therapy (range: 3â€“46) across the trial; 44 and 23 patients received at least 4 and 8 cycles respectively and 18 patients remained on trial for more than 12 cycles. The total number of cycles delivered across the entire trial and the number of patients requiring dose reductions for each drug is given in Table 
 <xref rid="Tab3" ref-type="table">3</xref>. The ixazomib dose delivered by cycle for the first 12 cycles, reflecting the need for dose reductions, is as shown in supplementary figure 
 <xref rid="MOESM3" ref-type="media">2</xref>. Overall, 40 patients have gone off study, the most common reason being alternate therapy, which was a stem cell transplant in 12 patients. The reasons for discontinuation of protocol treatment are as shown in Table 
 <xref rid="Tab2" ref-type="table">2</xref>. There were no treatment related deaths.
</p>
